These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8395486)

  • 1. Proton pump inhibitors in the management of GORD and PUD.
    Kenny E
    Ir Med J; 1993; 86(4):114. PubMed ID: 8395486
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacological profile of novel acid pump antagonist 7-(4-fluorobenzyloxy)-2,3-dimethyl-1-{[(1S,2S)-2-methyl cyclopropyl]methyl}-1H-pyrrolo[2,3-d]pyridazine (CS-526).
    Ito K; Kinoshita K; Tomizawa A; Inaba F; Morikawa-Inomata Y; Makino M; Tabata K; Shibakawa N
    J Pharmacol Exp Ther; 2007 Oct; 323(1):308-17. PubMed ID: 17630360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent advances in proton pump inhibitors and management of acid-peptic disorders.
    Jain KS; Shah AK; Bariwal J; Shelke SM; Kale AP; Jagtap JR; Bhosale AV
    Bioorg Med Chem; 2007 Feb; 15(3):1181-205. PubMed ID: 17150362
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton pump inhibitors and acid-related diseases.
    Sachs G
    Pharmacotherapy; 1997; 17(1):22-37. PubMed ID: 9017763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas.
    Jensen RT
    Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):4-19. PubMed ID: 16433886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potassium-competitive acid blockade: a new therapeutic strategy in acid-related diseases.
    Andersson K; Carlsson E
    Pharmacol Ther; 2005 Dec; 108(3):294-307. PubMed ID: 16000224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological and pharmacodynamic essentials of H(2)-receptor antagonists and proton pump inhibitors for the practising physician.
    Huang JQ; Hunt RH
    Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):355-70. PubMed ID: 11403532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: acid-related disease--what are the unmet clinical needs?
    Katz PO; Scheiman JM; Barkun AN
    Aliment Pharmacol Ther; 2006 Jun; 23 Suppl 2():9-22. PubMed ID: 16700899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why is the high grade inhibition of gastric acid secretion afforded by proton pump inhibitors often required for healing of reflux esophagitis? An epithelial perspective.
    Orlando RC
    Am J Gastroenterol; 1996 Sep; 91(9):1692-6. PubMed ID: 8792683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proton-pump inhibitors reduce the risk of uncomplicated peptic ulcer in elderly either acute or chronic users of aspirin/non-steroidal anti-inflammatory drugs.
    Pilotto A; Franceschi M; Leandro G; Paris F; Cascavilla L; Longo MG; Niro V; Andriulli A; Scarcelli C; Di Mario F
    Aliment Pharmacol Ther; 2004 Nov; 20(10):1091-7. PubMed ID: 15569111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Is there a place for the study of gastric mucosal defense mechanisms in the age of proton pump inhibitors and H. pylori?].
    Chinzon D; Zaterka S
    Arq Gastroenterol; 1996; 33(4):185-6. PubMed ID: 9302330
    [No Abstract]   [Full Text] [Related]  

  • 12. Review article: the pharmacodynamics and pharmacokinetics of proton pump inhibitors--overview and clinical implications.
    Robinson M
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():1-10. PubMed ID: 15496213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological targets in gastro-oesophageal reflux disease.
    Piche T; Galmiche JP
    Basic Clin Pharmacol Toxicol; 2005 Dec; 97(6):333-41. PubMed ID: 16364047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Review article: from gastrin to gastro-oesophageal reflux disease--a century of acid suppression.
    Malfertheiner P; Fass R; Quigley EM; Modlin IM; Malagelada JR; Moss SF; Holtmann G; Goh KL; Katelaris P; Stanghellini V; Talley NJ; Tytgat GN; Wright NA
    Aliment Pharmacol Ther; 2006 Mar; 23(6):683-90. PubMed ID: 16556170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developments in the inhibition of gastric acid secretion.
    Mössner J; Caca K
    Eur J Clin Invest; 2005 Aug; 35(8):469-75. PubMed ID: 16101666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Helicobacter pylori infection and antisecretory efficacy of proton-pump inhibitors in gastroesophageal reflux disease: a liaison dangereuse or an innocent interplay?
    Parente FR; Bargiggia SA; Anderloni A
    Scand J Gastroenterol; 2006 Oct; 41(10):1121-5. PubMed ID: 16990195
    [No Abstract]   [Full Text] [Related]  

  • 17. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
    Giral A; Celikel CA; Ozdogan O; Tözün N; Ulusoy NB; Kalayci C
    J Gastroenterol Hepatol; 2005 Dec; 20(12):1886-91. PubMed ID: 16336449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proton pump inhibitors to be used more?
    Andrawiss M
    Drug Discov Today; 2005 May; 10(9):607-8. PubMed ID: 15894221
    [No Abstract]   [Full Text] [Related]  

  • 19. Compliance with guidelines for proton pump inhibitor prescriptions in a department of geriatrics.
    Seite F; Delelis-Fanien AS; Valero S; Pradère C; Poupet JY; Ingrand P; Paccalin M
    J Am Geriatr Soc; 2009 Nov; 57(11):2169-70. PubMed ID: 20121973
    [No Abstract]   [Full Text] [Related]  

  • 20. Acid secretion and Helicobacter pylori.
    Sachs G; Meyer-Rosberg K; Scott DR; Melchers K; Shin J; Besancon M
    Digestion; 1997; 58 Suppl 1():8-13. PubMed ID: 9225081
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.